Key Insights

Highlights

Research Leaders

5 sponsors active, led by University of British Columbia

Related Conditions

Often studied with 12 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

Trial Status

Unknown2
Withdrawn1

Clinical Trials (3)

Showing 3 of 3 trials
NCT01457456Withdrawn

Biomarker for Morquio Disease (BioMorquio)

NCT04624789Unknown

Registry Gangliosidoses

NCT04320329UnknownPrimary

Natural History of Morquio B and Late-Onset of GM1 Gangliosidosis

Showing all 3 trials

Research Network

Active Sponsors

  • University of British Columbia1
  • Hospital de Clinicas de Porto Alegre1
  • Medical University of Graz1
  • SphinCS Lyso Gemeinnutzige UG (Haftungsbeschrankt)1
  • CENTOGENE GmbH Rostock1

Top Investigators

Related Conditions

  • Accumulation Of Mucopolysaccharides1
  • Morquio Syndrome1
  • Gangliosidoses1
  • Morquio Syndrome A1
  • Gm2 Activator Deficiency1

Activity Timeline